[
  {
    "ts": null,
    "headline": "Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura速 (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis",
    "summary": "WILMINGTON, Del., October 25, 2025--Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura速 (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis",
    "url": "https://finnhub.io/api/news?id=8a12cd1f203d7a77a3a1b0c11c59894e0eeab730d902b0192914dc1affa261e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761436500,
      "headline": "Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura速 (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis",
      "id": 137218533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., October 25, 2025--Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura速 (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis",
      "url": "https://finnhub.io/api/news?id=8a12cd1f203d7a77a3a1b0c11c59894e0eeab730d902b0192914dc1affa261e2"
    }
  }
]